PCM
NGM

Pentwater Capital Management’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Pentwater Capital Management’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,000
Closed -$185K – 165
2019
Q4 		$185K Sell
10,000
-9,100
-48% -$133K ﹤0.01% 146
2019
Q3 		$265K Sell
19,100
-2,000
-9% -$30K ﹤0.01% 146
2019
Q2 		$309K Buy
+21,100
New +$309K ﹤0.01% 168

Other funds holding NGM

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
Greenspring Associates Owings Mills, Maryland $1.48B AUM 61.93% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Pentwater Capital Management's NGM Position: Q1 2020 in Review

Pentwater Capital Management sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2020, closing a stake of 10,000 shares — an estimated $185K sold.

Pentwater Capital Management first reported a position in NGM in Q2 2019 and held it in 3 quarters. The position peaked at $309K in Q2 2019. 73 funds tracked by Wall St. Rank hold NGM as of Q1 2020.

  • Pentwater Capital Management reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Pentwater Capital Management sold 10,000 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $185K.
  • Pentwater Capital Management first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 3 quarters.
  • Pentwater Capital Management's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $309K in Q2 2019.
  • 73 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on Pentwater Capital Management's 13F filing for Q1 2020, filed 15 May 2020.